Substandard drugs: a potential crisis for public health

@article{Johnston2013SubstandardDA,
  title={Substandard drugs: a potential crisis for public health},
  author={Atholl Johnston and David W Holt},
  journal={British Journal of Clinical Pharmacology},
  year={2013},
  volume={78},
  pages={218 - 243}
}
  • A. JohnstonD. Holt
  • Published 29 November 2013
  • Medicine, Political Science
  • British Journal of Clinical Pharmacology
Poor‐quality medicines present a serious public health problem, particularly in emerging economies and developing countries, and may have a significant impact on the national clinical and economic burden. Attention has largely focused on the increasing availability of deliberately falsified drugs, but substandard medicines are also reaching patients because of poor manufacturing and quality‐control practices in the production of genuine drugs (either branded or generic). Substandard medicines… 

Low-quality of some generic medicinal products represents a matter for growing concern.

A global strategy that unifies the efforts of all the stakeholders, including drug manufacturers, healthcare providers, Governments, health professionals, patients and judicial systems are needed to protect the drug chain supply and ensure that only high-quality GMPs are available for use.

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance

This work adapts principles used for disease outbreak response to suggest a case-finding system that uses secondary data to flag poor quality medicines and a risk-based sentinel surveillance system which concentrates resources on measuring the prevalence of substandard and falsified medicines in risk clusters in which they are most likely to be found.

DEVELOPING A CHALLENGES LANDSCAPE RELATING TO DRUG SAFETY, PROVISION, AND DISTRIBUTION IN RESOURCE-LIMITED SETTINGS FOR THE CASE OF HIV/AIDS

Research indicates that it is often the case that these ‘niche drug provision systems’ face many challenges with the quality of new-generation drugs and the implementation of effective pharmacovigilance (PV)1 systems for the reporting of adverse drug reactions.

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance (Preprint)

UNSTRUCTURED The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country

Tackling the Problems Associated with Antimalarial Medicines of Poor Quality

The chapter discusses how the implementation of strategies such as the WHO Prequalification Program, the African Medicine Registration Harmonization initiative, and the ethical production of medicines by pharmaceutical companies help to ensure that antimalarial therapies marketed in low-income, malaria-endemic countries are quality assured.

Legal Uncertainty—The Gray Area around Substandard Medicines: Where Public Health Meets Law

A “legal levers matrix” is presented that may assist legislators and policymakers evaluate the adequacy of measures to address the problem of poor-quality medicines, particularly in terms of their configuration and underscores the importance of fostering dialogue between medical/public health and the legal/regulatory communities.

Follow-on products for treatment of multiple sclerosis in Latin America: An update

  • J. Correale
  • Medicine, Political Science
    Journal of the Neurological Sciences
  • 2017

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Nonproprietary medicines for multiple sclerosis, particularly fingolimod, that are not identical to proprietary versions and could thus fail to meet efficacy expectations or have different impact on the safety of patients with multiple sclerosis are reviewed.

A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives

To address online sales of substandard and falsified medicines (SFMs), more robust research, greater awareness/educational programmes, analytical detection methods and more stringent online global governance are required.
...

References

SHOWING 1-10 OF 219 REFERENCES

Substandard medicines in resource‐poor settings: a problem that can no longer be ignored

Governments in rich countries should not tolerate the export of substandard pharmaceutical products to poor countries, while developing country governments should improve their ability to detect substandard medicines.

Countering the Problem of Falsified and Substandard Drugs

The US Food and Drug Administration commissioned the Institute of Medicine to investigate the global problem of falsified and substandard drugs, considering the causes and possible solutions to this international public health crisis.

The WWARN Antimalarial Quality Surveyor

A new Antimalarial Quality Scientific Group is built that aims to collate information and stimulate discussion on the epidemiology of poor quality antimalarials, and facilitate improvements both in sampling and analytical methodology, and advocate for more investment in this, but neglected, aspect of public health.

Substandard anti-malarial drugs in Burkina Faso

These findings provide further evidence for the wide-spread existence of substandard anti-malarial medications in Africa and call for strengthening of the regulatory and quality control capacity of affected countries, particularly in view of the now wider available and substantially more costly artemisinin-based combination therapies.

Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence.

In this article, the available evidence in peer-reviewed articles and World Wide Web information resources regarding the issue of counterfeit antimicrobial drugs are reviewed.

Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study

The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies in the private sector risks patient safety and, through drug resistance, places the future of malaria treatment at risk globally.

[Biosimilar medicines].

  • P. GjersvikS. Madsen
  • Medicine, Biology
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
  • 2015
Biosimilar medicines are usually approved via an abbreviated licensing process with a limited clinical database, hence significant postapproval commitments are required to further characterise immunogenic potential and monitor adverse drug reactions.

Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries.

The findings in this review support the strong contention that substandard and counterfeit antimicrobials are available in the developing world in very high proportions and public health interventions in developing countries should include quality control of antimicrobial drugs as an integral part of program implementation.

Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication.

  • L. Basco
  • Medicine
    The American journal of tropical medicine and hygiene
  • 2004
Investigation of the quality of chloroquine, quinine, and sulfadoxine-pyrimethamine obtained from illegitimate sector in urban and rural areas in Cameroon found that self-medication with antimalarial drugs purchased from unofficial vendors is not a reliable strategy to diminish morbidity and mortality.
...